Objectives
To assess the efficacy of Infliximab (IFX) and adalimumab (ADA) in refractory uveitis of Behçet’s syndrome.
Methods
Study of 63 patients followed in the Uveitis Clinic of 24 hospitals. All of them were refractory to conventional therapy with systemic steroids and ≥1 immunosuppressive drug. Efficacy was evaluated according to SUN criteria, and macular thickness by optical coherence tomography (OCT). Outcomes and comparisons were made at week 1, week 2, month 1, month 6 and at 1 and 2 years. Statistical analyses were performed using the STATISTICA (Statsoft). Results were expressed: mean±1SD (normally distributed variables) or median [25th-75th interquartile range-IQR] (not normally). Continuous variables were compared with the Wilcoxon test.
Results
We studied 63 patients/110 affected eyes (36M, 27W), mean age 38.9±9.0 years. Prior to anti-TNF, patients had received ivMprednisolone (n=20), cyclosporine (CyA) (n=53), methotrexate (MTX) (n=31) and azathioprine (AZA) (n=30). IFX was the anti-TNF more commonly used (64%). The remaining patients (36%) were treated with ADA. 14 patients (22%) required switching (12 from IFX→ADA; 2 ADA→IFX). Dosage: IFX 5 mg/kg/iv every 4-8 weeks or ADA 40 mgsc/2weeks. The median[IQR] follow-up from the onset of anti-TNF was 36 [20-60] months. Significant improvement of Visual acuity (VA), Tyndall and vitritis was observed soon (week 1). At 2 years,VA improved from 0.5±0.3 at basal to 0.7±0.3 (p<0.001), Tyndall from a median of 1.07 [0-2] to 0.09 [0-0] (p<0.001) and vitritis, from 1.0 [0-2] to 0.0 [0-0], respectively. Initially,17 patients (24 eyes) had cystoid macular edema (CME). Following anti-TNF OCT decreased from 320.2±120.9 to 260.4±42.8 at 2 years (p<0.001). The most serious side effect was a miliary tuberculosis in 1 patient at month 1 after the onset of IFX.
Basal (N)1 week1 month6 months1 year2 year
patients/eyes(% inactive eyes)(% inactive eyes)(% inactive eyes)(% inactive eyes)(% inactive eyes)
Tyndall42/6828%97%80%88%93%
Vitritis53/8533%55%75%84%90%
Choroiditis10/1839%45%100%100%100%
Retinal vasculitis55/8525%59%90%97%95%
CME (>300μm)17/2413%13%63%63%79%
*Inactive if: anterior inflammation Tyndall = 0, vitritis = 0, choroiditis, retinitis/retinal vasculitis: no activity and CME if OCT <250.
Conclusions
Monoclonal anti-TNF therapy is effective and relatively safe in uveitis of Behcet’s syndrome refractory to conventional therapy.
Disclosure of Interest
None Declared
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.